Drugs / MNK155
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02767349 | Jan 2016 → Apr 2017 | — | Mallinckrodt | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02381132 Comparator | Nov 2014 → Dec 2015 | — | Neil Singla | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MNK 155 | “The main study drug of interest in this study is MNK 155.” NCT02381132 ↗ |
| Route | Oral | “oral MNK155 and Norco® 7.5mg/325mg” NCT02381132 ↗ |